|
*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, Frankly and this Station make no warranties or representations in connection therewith.
|
Medicine & Pharmaceuticals News Releases via PRNewswireMore>>
Cell Culture Market's Valuation Will Reach US$ 29,000.0 Mn by 2025, Says TMR
Cell Culture Market's Valuation Will Reach US$ 29,000.0 Mn by 2025, Says TMR
The global cell culture market was valued at US$13,000.0 mn in 2016, and is further expected to register a revenue worth around US$29,000.0 mn by 2025. Such a growth in terms of revenue gained is expected to occur...More \232aThe global cell culture market was valued at US$13,000.0 mn in 2016, and is further expected to register a revenue worth around US$29,000.0 mn by 2025. Such a growth in terms of revenue gained is expected to occur...More \232aMazor Robotics to Report First Quarter Financial Results on May 14, 2018
Mazor Robotics to Report First Quarter Financial Results on May 14, 2018
Mazor Robotics Ltd. (TASE: MZOR) (NASDAQGM: MZOR), a pioneer and a leader in the field of surgical robotic guidance systems, announced today that it will report financial results for the first quarter ended March 31, 2018,...More \232aMazor Robotics Ltd. (TASE: MZOR) (NASDAQGM: MZOR), a pioneer and a leader in the field of surgical robotic guidance systems, announced today that it will report financial results for the first quarter ended March 31, 2018,...More \232aNeurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD),...More \232aNeurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD),...More \232aDarling Ingredients Inc. Announces Pricing of Private Offering of €515 Million of Unsecured Senior Notes due 2026 by Darling Global Finance B.V.
Darling Ingredients Inc. Announces Pricing of Private Offering of €515 Million of Unsecured Senior Notes due 2026 by Darling Global Finance B.V.
Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced that Darling Global Finance B.V. (the "Issuer"), an indirect, wholly-owned subsidiary of the Company incorporated under the laws of The...More \232aDarling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced that Darling Global Finance B.V. (the "Issuer"), an indirect, wholly-owned subsidiary of the Company incorporated under the laws of The...More \232aAsembia Adds New Patient Support Center Location
Asembia Adds New Patient Support Center Location
Asembia, the leading provider of collaborative solutions and group purchasing services to the specialty pharmacy industry, is pleased to announce the opening of an additional office space in Trevose, PA. With four...More \232aAsembia, the leading provider of collaborative solutions and group purchasing services to the specialty pharmacy industry, is pleased to announce the opening of an additional office space in Trevose, PA. With four...More \232aGlobal Market Study on Atrophic Scar Treatment: Close Fight Between APAC and Europe Markets in Terms of both Revenue Share and Growth Rate
Global Market Study on Atrophic Scar Treatment: Close Fight Between APAC and Europe Markets in Terms of both Revenue Share and Growth Rate
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and...More \232aDespite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and...More \232aDatum Dental, Ltd. and Dentsply Sirona Implants Enter Distribution Agreement in the USA
Datum Dental, Ltd. and Dentsply Sirona Implants Enter Distribution Agreement in the USA
Datum Dental, Ltd, leading provider of OSSIX® brand innovative solutions for bone and tissue regeneration for dentistry, announces expansion of its global distribution network. In the USA, Dentsply Sirona Implants is now...More \232aDatum Dental, Ltd, leading provider of OSSIX® brand innovative solutions for bone and tissue regeneration for dentistry, announces expansion of its global distribution network. In the USA, Dentsply Sirona Implants is now...More \232aEP Catheter Ablation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026
EP Catheter Ablation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026
In an exclusive report, Transparency Market Research has compiled a range of sections analyzing the expansion of the global EP catheter ablation market for the assessment period, 2017-2026. The study delivers insightful...More \232aIn an exclusive report, Transparency Market Research has compiled a range of sections analyzing the expansion of the global EP catheter ablation market for the assessment period, 2017-2026. The study delivers insightful...More \232aFDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...More \232aOrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...More \232aGtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops
GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is informing stockholders that GtreeBNT,...More \232aRegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is informing stockholders that GtreeBNT,...More \232aDURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH). DUR-928, the lead investigational product in our...More \232aDURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH). DUR-928, the lead investigational product in our...More \232aQuotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, Depomed, and DURECT
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, Depomed, and DURECT
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, APRI, DEPO, and DRRX which can be accessed for free by signing up to...More \232aWallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, APRI, DEPO, and DRRX which can be accessed for free by signing up to...More \232aPreliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting
Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral...More \232aPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral...More \232aAmgen Reports First Quarter 2018 Financial Results
Amgen Reports First Quarter 2018 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include:More \232aAmgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include:More \232aBrooks Automation Announces the Acquisition of a Canadian Biorepository
Brooks Automation Announces the Acquisition of a Canadian Biorepository
Brooks Automation, Inc. (Nasdaq: BRKS) announced today that it has acquired BioSpeciMan Corporation, a Canadian provider of storage services for biological sample materials headquartered in Montreal, Canada with operations...More \232aBrooks Automation, Inc. (Nasdaq: BRKS) announced today that it has acquired BioSpeciMan Corporation, a Canadian provider of storage services for biological sample materials headquartered in Montreal, Canada with operations...More \232aGlobal Student Microscope Market 2018-2022
Global Student Microscope Market 2018-2022
About Student Microscope A student microscope is defined as an optical microscope that is used in primary, secondary and tertiary educational institutions. Read the full report: https://www.reportlinker.com/p03588365 ...More \232aAbout Student Microscope A student microscope is defined as an optical microscope that is used in primary, secondary and tertiary educational institutions. Read the full report: https://www.reportlinker.com/p03588365 ...More \232aGENEWIZ And Pacific Biosciences Announce Winner Of The 2017 Structural Variant SMRT® Grant Program
GENEWIZ And Pacific Biosciences Announce Winner Of The 2017 Structural Variant SMRT® Grant Program
Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read, high-resolution sequencing, and GENEWIZ, a leading global genomics service provider, are pleased to announce that Professor Stephen Scherer,...More \232aPacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read, high-resolution sequencing, and GENEWIZ, a leading global genomics service provider, are pleased to announce that Professor Stephen Scherer,...More \232aChild Resistant Closures Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Child Resistant Closures Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Global Child Resistant Closures Market: Overview This Transparency Market Research report examines the global child resistant closures market for the forecast period 2017–2025. The primary objective of the report is to...More \232aGlobal Child Resistant Closures Market: Overview This Transparency Market Research report examines the global child resistant closures market for the forecast period 2017–2025. The primary objective of the report is to...More \232aPhytonutrients Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast - 2017 - 2025
Phytonutrients Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast - 2017 - 2025
Global Phytonutrients Market: Overview This report analyzes and forecasts the market for phytonutrients at the global and regional level.The market has been forecast based on revenue (US$ Mn) and Volume (Tons) from 2017 to...More \232aGlobal Phytonutrients Market: Overview This report analyzes and forecasts the market for phytonutrients at the global and regional level.The market has been forecast based on revenue (US$ Mn) and Volume (Tons) from 2017 to...More \232aThousands of Managed Care Pharmacists and Health Care Stakeholders Gather in Boston for the 2018 Annual Meeting of the Academy of Managed Care Pharmacy (AMCP)
Thousands of Managed Care Pharmacists and Health Care Stakeholders Gather in Boston for the 2018 Annual Meeting of the Academy of Managed Care Pharmacy (AMCP)
More than 4,000 managed care pharmacy professionals and stakeholders from across the country have gathered in Boston this week to attend the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy...More \232aMore than 4,000 managed care pharmacy professionals and stakeholders from across the country have gathered in Boston this week to attend the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy...More \232aAmicrobe, Inc., Developer Of Novel Technology For Antibiotic Resistance, Adds Safety Application To Intellectual Property Portfolio
Amicrobe, Inc., Developer Of Novel Technology For Antibiotic Resistance, Adds Safety Application To Intellectual Property Portfolio
Amicrobe, Inc. uses advanced bioengineering principles to develop novel antimicrobial products for the era of antibiotic resistance. Today, the company announced that it has filed an international PCT patent application...More \232aAmicrobe, Inc. uses advanced bioengineering principles to develop novel antimicrobial products for the era of antibiotic resistance. Today, the company announced that it has filed an international PCT patent application...More \232aAutoimmune Disease and Metal Exposure: What You Need to Know
Autoimmune Disease and Metal Exposure: What You Need to Know
Scientific research is repeatedly demonstrating that metal exposure can be a contributing factor to autoimmune disease, warns the International Academy of Oral Medicine and Toxicology (IAOMT).More \232aScientific research is repeatedly demonstrating that metal exposure can be a contributing factor to autoimmune disease, warns the International Academy of Oral Medicine and Toxicology (IAOMT).More \232aGlobal Prosthetic Robot Arm Market 2018-2022: Leading Trends Include 3D-Printed Prosthetic Robot Arms, Adoption of Innovative Business Models & Improvements in the Sense of Touch
Global Prosthetic Robot Arm Market 2018-2022: Leading Trends Include 3D-Printed Prosthetic Robot Arms, Adoption of Innovative Business Models & Improvements in the Sense of Touch
The "Global Prosthetic Robot Arm Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global prosthetic robot arm market to grow at a CAGR of 11.28% during the period 2018-2022. Global...More \232aThe "Global Prosthetic Robot Arm Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global prosthetic robot arm market to grow at a CAGR of 11.28% during the period 2018-2022. Global...More \232aUrovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Urovant Sciences, a global biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it has strengthened its management team through the appointment of five senior...More \232aUrovant Sciences, a global biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it has strengthened its management team through the appointment of five senior...More \232aIntec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were...More \232aIntec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were...More \232aConnect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Ra, Into Clinical Development
Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Ra, Into Clinical Development
Connect Biopharmaceuticals, Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic...More \232aConnect Biopharmaceuticals, Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic...More \232aCRH Medical Corporation To Announce 2018 First Quarter Results on April 30, 2018
CRH Medical Corporation To Announce 2018 First Quarter Results on April 30, 2018
VANCOUVER, April 23, 2018 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), plans to release its results for the quarter ended March 31, 2018, on Monday, April 30, 2018 after market close.More \232aVANCOUVER, April 23, 2018 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), plans to release its results for the quarter ended March 31, 2018, on Monday, April 30, 2018 after market close.More \232aBiostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice
Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on received a notification letter from...More \232aBiostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on received a notification letter from...More \232aApplied BioMath, LLC Announces Collaboration with Checkpoint Therapeutics for Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Modeling in Immuno-Oncology
Applied BioMath, LLC Announces Collaboration with Checkpoint Therapeutics for Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Modeling in Immuno-Oncology
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic mathematical modeling, simulation, and analysis to de-risk therapeutic research and development, today announced a collaboration with...More \232aApplied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic mathematical modeling, simulation, and analysis to de-risk therapeutic research and development, today announced a collaboration with...More \232aGlobal Medical Device Market 2018 with Forecasts to 2023 - Driven by Healthcare Expenditure / Technological Development / Aging Population / Chronic Diseases
Global Medical Device Market 2018 with Forecasts to 2023 - Driven by Healthcare Expenditure / Technological Development / Aging Population / Chronic Diseases
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 23, 2018 /PRNewswire/ -- The "Medical Device Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com'...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 23, 2018 /PRNewswire/ -- The "Medical Device Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com'...More \232aThe Kroger Co. and Cardinal Health to Co-Host Drug Take-Back Events Across 26 States on April 28
The Kroger Co. and Cardinal Health to Co-Host Drug Take-Back Events Across 26 States on April 28
Today, Kroger (NYSE: KR) and Cardinal Health (NYSE: CAH) announced the companies will host joint drug take-back events at more than 100 Kroger Family of Pharmacies locations from 10 a.m. – 2 p.m. local time on April 28,...More \232aToday, Kroger (NYSE: KR) and Cardinal Health (NYSE: CAH) announced the companies will host joint drug take-back events at more than 100 Kroger Family of Pharmacies locations from 10 a.m. – 2 p.m. local time on April 28,...More \232aOrexigen Therapeutics, Inc. Enters Agreement for Sale of Company
Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company
Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to...More \232aOrexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to...More \232aGlobal Patient Scales Industry
Global Patient Scales Industry
This report analyzes the worldwide markets for Patient Scales in US$ Thousand by the following Product Segments: Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales. Download the full report:...More \232aThis report analyzes the worldwide markets for Patient Scales in US$ Thousand by the following Product Segments: Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales. Download the full report:...More \232aSurgical Drapes and Gowns: Global Market Report 2018-2023 - Growing Incidence of Hospital-Acquired Infections is Driving the Market
Surgical Drapes and Gowns: Global Market Report 2018-2023 - Growing Incidence of Hospital-Acquired Infections is Driving the Market
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 23, 2018 /PRNewswire/ -- The "Surgical Drapes and Gowns Market by Type (Drapes, Gown), Utility (Reusable, Disposable), End User (Hospital) - Global Foreca...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 23, 2018 /PRNewswire/ -- The "Surgical Drapes and Gowns Market by Type (Drapes, Gown), Utility (Reusable, Disposable), End User (Hospital) - Global Foreca...More \232aCanon Virginia, Inc. to Showcase Company's Advanced Manufacturing Technologies
Canon Virginia, Inc. to Showcase Company's Advanced Manufacturing Technologies
Demonstrating its advanced manufacturing technologies and an innovative approach to custom manufacturing, Canon Virginia, Inc. (CVI), a wholly owned subsidiary of Canon U.S.A., Inc., will attend NPE 2018: The Plastics...More \232aDemonstrating its advanced manufacturing technologies and an innovative approach to custom manufacturing, Canon Virginia, Inc. (CVI), a wholly owned subsidiary of Canon U.S.A., Inc., will attend NPE 2018: The Plastics...More \232aREACTINE® Canada petitioning for the creation of the first allergy emoji
REACTINE® Canada petitioning for the creation of the first allergy emoji
Allergy relief brand to help allergy sufferers share how they really feelMore \232aAllergy relief brand to help allergy sufferers share how they really feelMore \232aTheravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV® (telavancin) were presented at the 28th European Congress of...More \232aTheravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV® (telavancin) were presented at the 28th European Congress of...More \232aDr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal's research and development...More \232aGrünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal's research and development...More \232aDarling Ingredients Inc. Announces Private Offering of €515 Million of Unsecured Senior Notes by Darling Global Finance B.V.
Darling Ingredients Inc. Announces Private Offering of €515 Million of Unsecured Senior Notes by Darling Global Finance B.V.
Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced that Darling Global Finance B.V. (the "Issuer"), an indirect, wholly-owned subsidiary of the Company incorporated under the laws of The...More \232aDarling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced that Darling Global Finance B.V. (the "Issuer"), an indirect, wholly-owned subsidiary of the Company incorporated under the laws of The...More \232aJuntendo University Research: Malaria in Africa is Developing Resistance to Drugs
Juntendo University Research: Malaria in Africa is Developing Resistance to Drugs
Annual deaths from malaria are decreasing, but the disease is still a global health problem, with 216 million new cases estimated in 2016 alone, with 90% occurring in Africa. Toshihiro Mita from the Juntendo University...More \232aAnnual deaths from malaria are decreasing, but the disease is still a global health problem, with 216 million new cases estimated in 2016 alone, with 90% occurring in Africa. Toshihiro Mita from the Juntendo University...More \232aBiohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Tr
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Tr
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the results of key secondary outcome measures from Phase 3 clinical trials (BHV3000-301 and BHV3000-302) of rimegepant, the first oral CGRP receptor...More \232aBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the results of key secondary outcome measures from Phase 3 clinical trials (BHV3000-301 and BHV3000-302) of rimegepant, the first oral CGRP receptor...More \232aCreation of Inceptua Clinical Trial Services Marks New Era for the Company
Creation of Inceptua Clinical Trial Services Marks New Era for the Company
Inceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including...More \232aInceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including...More \232aMylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual...More \232aGlobal pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual...More \232aProgress in Migraine Research, Promius Announces Presentations for the 70th American Academy of Neurology Annual Meeting
Progress in Migraine Research, Promius Announces Presentations for the 70th American Academy of Neurology Annual Meeting
Promius Pharma LLC announces its presentations for the 70th American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA, April 21-27, 2018.More \232aPromius Pharma LLC announces its presentations for the 70th American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA, April 21-27, 2018.More \232aLilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Eli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE trial evaluating CYRAMZA® (ramucirumab) in combination with docetaxel in...More \232aEli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE trial evaluating CYRAMZA® (ramucirumab) in combination with docetaxel in...More \232aIterum Therapeutics Presents Data on Prevalence of Resistant Infections and Activity of its Novel Antibiotic Sulopenem
Iterum Therapeutics Presents Data on Prevalence of Resistant Infections and Activity of its Novel Antibiotic Sulopenem
Iterum Therapeutics plc, a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will deliver a mini-oral presentation and two additional posters at the European Congress...More \232aIterum Therapeutics plc, a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will deliver a mini-oral presentation and two additional posters at the European Congress...More \232aCSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
Global biotherapeutics leader CSL Behring today announced that it will host an Industry Therapeutic Update at the 2018 annual meeting of the American Academy of Neurology (AAN) which will focus on neuromuscular medical...More \232aGlobal biotherapeutics leader CSL Behring today announced that it will host an Industry Therapeutic Update at the 2018 annual meeting of the American Academy of Neurology (AAN) which will focus on neuromuscular medical...More \232aFDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (sNDA) which seeks a new indication for...More \232aVeloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (sNDA) which seeks a new indication for...More \232aBruker Introduces Bologna Workflow for Rapid and Cost-Effective Clinical Microbiology Diagnosis of Bloodstream Infections with Broad Species Coverage
Bruker Introduces Bologna Workflow for Rapid and Cost-Effective Clinical Microbiology Diagnosis of Bloodstream Infections with Broad Species Coverage
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Bruker Corporation 60-90 Minute Microbial ID of 2,700 Species from Positive Blood Cultures, Combined with Functional Testing of Cephalosporin- and Carbapenem-Resistance on MALDI Biotyper®, Ad...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Bruker Corporation 60-90 Minute Microbial ID of 2,700 Species from Positive Blood Cultures, Combined with Functional Testing of Cephalosporin- and Carbapenem-Resistance on MALDI Biotyper®, Ad...More \232aU.S. Sleep Market 2018: Competitive & Operating Analysis 1995-2017 & 2018-2023 Featuring ResMed, Respironics, SleepMed, Novasom, Tempur Sealy, Sleep Numbero & Simmons Serta
U.S. Sleep Market 2018: Competitive & Operating Analysis 1995-2017 & 2018-2023 Featuring ResMed, Respironics, SleepMed, Novasom, Tempur Sealy, Sleep Numbero & Simmons Serta
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 20, 2018 /PRNewswire/ -- The "The U.S. Sleep Market 2018: Competitive & Operating Analysis" report has been added to ResearchAndMarkets.com's offe...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 20, 2018 /PRNewswire/ -- The "The U.S. Sleep Market 2018: Competitive & Operating Analysis" report has been added to ResearchAndMarkets.com's offe...More \232aShimadzu Corporation Releases the KPR-300 Kalnew Precision Refractometer
Shimadzu Corporation Releases the KPR-300 Kalnew Precision Refractometer
High-accuracy multi-wavelength digital refractometer with the V-block method, optimal for measurements of optical materials Shimadzu Corporation has released the KPR-300 Kalnew precision refractometer in North America....More \232aHigh-accuracy multi-wavelength digital refractometer with the V-block method, optimal for measurements of optical materials Shimadzu Corporation has released the KPR-300 Kalnew precision refractometer in North America....More \232aRaySearch Partners With Heidelberg University Hospital on RayCare OIS
RaySearch Partners With Heidelberg University Hospital on RayCare OIS
Heidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB (publ) to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting...More \232aHeidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB (publ) to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting...More \232a/C O R R E C T I O N -- Hologic, Inc./
/C O R R E C T I O N -- Hologic, Inc./
Hologic, Inc. (Nasdaq: HOLX) announced today that in a new study, women treated with NovaSure® endometrial ablation reported a higher one-year amenorrhea (absence of menstruation) rate, better quality of life (QoL)...More \232aHologic, Inc. (Nasdaq: HOLX) announced today that in a new study, women treated with NovaSure® endometrial ablation reported a higher one-year amenorrhea (absence of menstruation) rate, better quality of life (QoL)...More \232aWomen Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea Rates than Those Treated with Minerva
Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea Rates than Those Treated with Minerva
Hologic, Inc. (Nasdaq: HOLX) announced today that in a new study, women treated with NovaSure® endometrial ablation reported a higher one-year amenorrhea (absence of menstruation) rate, better quality of life (QoL)...More \232aHologic, Inc. (Nasdaq: HOLX) announced today that in a new study, women treated with NovaSure® endometrial ablation reported a higher one-year amenorrhea (absence of menstruation) rate, better quality of life (QoL)...More \232aEuropean Pharma E-commerce Market 2018-2022 - Illegal and Counterfeit Trading of Drugs Through e-Pharmacy Presents Major Market Challenges
European Pharma E-commerce Market 2018-2022 - Illegal and Counterfeit Trading of Drugs Through e-Pharmacy Presents Major Market Challenges
The "Pharma E-commerce Market in Europe 2018-2022" report has been added to ResearchAndMarkets.com's offering. The pharma e-commerce market in Europe to grow at a CAGR of 13.82% during the period 2018-2022. Pharma...More \232aThe "Pharma E-commerce Market in Europe 2018-2022" report has been added to ResearchAndMarkets.com's offering. The pharma e-commerce market in Europe to grow at a CAGR of 13.82% during the period 2018-2022. Pharma...More \232aThe Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months
The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months
Seqirus, a CSL company (ASX: CSL) and a leading innovator in influenza vaccines, today announced that The Lancet Respiratory Medicine published results from a Phase 3, randomized, head-to-head efficacy study that found an...More \232aSeqirus, a CSL company (ASX: CSL) and a leading innovator in influenza vaccines, today announced that The Lancet Respiratory Medicine published results from a Phase 3, randomized, head-to-head efficacy study that found an...More \232aGlobal Operating Tables Industry
Global Operating Tables Industry
This report analyzes the worldwide markets for Operating Tables in US$ Thousand by the following Product Segments: General Operating Tables, and Specialty Operating Tables. Download the full report:...More \232aThis report analyzes the worldwide markets for Operating Tables in US$ Thousand by the following Product Segments: General Operating Tables, and Specialty Operating Tables. Download the full report:...More \232aGlobal Intravenous Equipment Industry
Global Intravenous Equipment Industry
This report analyzes the worldwide markets for Intravenous Equipment in US$ Thousand by the following Segments: Intravenous Catheters, and Intravenous Infusion Pumps and Sets. Download the full report:...More \232aThis report analyzes the worldwide markets for Intravenous Equipment in US$ Thousand by the following Segments: Intravenous Catheters, and Intravenous Infusion Pumps and Sets. Download the full report:...More \232aOptical Microscopes Market to Gain US$ 2.5 Bn by 2025, Says TMR
Optical Microscopes Market to Gain US$ 2.5 Bn by 2025, Says TMR
The global optical microscopes market was valued at around US$ 1.5 Bn in 2016 and is anticipated to expand at a CAGR of around 6% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR)...More \232aThe global optical microscopes market was valued at around US$ 1.5 Bn in 2016 and is anticipated to expand at a CAGR of around 6% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR)...More \232aEisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA
Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA
Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include analyses on long-term...More \232aEisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include analyses on long-term...More \232aBerkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
Berkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today Sanofi purchased the Beacon platform to accelerate their cell line...More \232aBerkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today Sanofi purchased the Beacon platform to accelerate their cell line...More \232aZS Teams Up with Valkre Solutions to Enhance Its Key Account Management Offering
ZS Teams Up with Valkre Solutions to Enhance Its Key Account Management Offering
Global sales and marketing firm ZS is excited to announce a new partnership with Valkre Solutions, an account-based sales and marketing cloud software provider. ZS will leverage Valkre's software to transform the...More \232aGlobal sales and marketing firm ZS is excited to announce a new partnership with Valkre Solutions, an account-based sales and marketing cloud software provider. ZS will leverage Valkre's software to transform the...More \232aWuXi AppTec Expands Site in the United States for Drug Development Testing Services
WuXi AppTec Expands Site in the United States for Drug Development Testing Services
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey....More \232aWuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey....More \232aUS FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have...More \232aAstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have...More \232aBenevolentAI Raises $115 Million to Extend Its Leading Global Position in the Field of AI Enabled Drug Development
BenevolentAI Raises $115 Million to Extend Its Leading Global Position in the Field of AI Enabled Drug Development
BenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector. The majority of...More \232aBenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector. The majority of...More \232aNeurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive...More \232aNeurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive...More \232aCircular Dichroism Spectrometers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Circular Dichroism Spectrometers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Global Circular Dichroism (CD) Spectrometers Market: Overview Circular dichroism (CD) spectrometer is an analytical instrument used to analyze the molecular structure and chiral activity of organic molecules.It is widely...More \232aGlobal Circular Dichroism (CD) Spectrometers Market: Overview Circular dichroism (CD) spectrometer is an analytical instrument used to analyze the molecular structure and chiral activity of organic molecules.It is widely...More \232aXultophy® approved in Canada for the treatment of adults with type 2 diabetes
Xultophy® approved in Canada for the treatment of adults with type 2 diabetes
Once-daily Xultophy® has been shown to help patients achieve blood glucose targetsMore \232aOnce-daily Xultophy® has been shown to help patients achieve blood glucose targetsMore \232aSoftheon Marketplace Cloud to eliminate use of Healthcare.gov for real-time health plan enrollment
Softheon Marketplace Cloud to eliminate use of Healthcare.gov for real-time health plan enrollment
Softheon, a national leader in cloud-based health insurance exchange integration and services, announced today its private-label enrollment solution, which provides Enhanced Direct Enrollment-as-a-service (EDE); a unified...More \232aSoftheon, a national leader in cloud-based health insurance exchange integration and services, announced today its private-label enrollment solution, which provides Enhanced Direct Enrollment-as-a-service (EDE); a unified...More \232aHoward University Hospital and DCPS Team Up for Stop the Bleed Initiative
Howard University Hospital and DCPS Team Up for Stop the Bleed Initiative
Howard University Hospital's (HUH) Department of Trauma and Critical Care recently teamed up with staff members at H.D. Woodson Senior High School in Washington, D.C., to conduct a "Stop the Bleed" Training.More \232aHoward University Hospital's (HUH) Department of Trauma and Critical Care recently teamed up with staff members at H.D. Woodson Senior High School in Washington, D.C., to conduct a "Stop the Bleed" Training.More \232aGlobal Single-use Bioprocessing Material Market Expected to Reach $9,342.1 Million by 2023 - Allied Market Research
Global Single-use Bioprocessing Material Market Expected to Reach $9,342.1 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "Single-use Bioprocessing Material Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global single-use...More \232aAccording to a new report published by Allied Market Research, titled, "Single-use Bioprocessing Material Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global single-use...More \232aGlobal Endoscopy Devices Market Overview to 2024 with Contact Details of 369 Companies
Global Endoscopy Devices Market Overview to 2024 with Contact Details of 369 Companies
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 18, 2018 /PRNewswire/ -- The "Endoscopy Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. Gastrointest...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 18, 2018 /PRNewswire/ -- The "Endoscopy Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. Gastrointest...More \232aApplied BioMath, LLC Collaborates with Xencor for Semi-Mechanistic PK/PD Modeling of XmAb®24306, Xencor's Lead IL15 Program for the Treatment of Solid Tumors
Applied BioMath, LLC Collaborates with Xencor for Semi-Mechanistic PK/PD Modeling of XmAb®24306, Xencor's Lead IL15 Program for the Treatment of Solid Tumors
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform...More \232aApplied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform...More \232aMesa Biotech to Demonstrate New Molecular POC Testing Platform at the European Congress of Clinical Microbiology and Infectious Diseases
Mesa Biotech to Demonstrate New Molecular POC Testing Platform at the European Congress of Clinical Microbiology and Infectious Diseases
Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease...More \232aMesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease...More \232aXencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical...More \232aXencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical...More \232aNavigator Business Solutions Releases Turnkey SAP Cloud ERP Solutions for Medical Device and Pharmaceutical Manufacturing Industries
Navigator Business Solutions Releases Turnkey SAP Cloud ERP Solutions for Medical Device and Pharmaceutical Manufacturing Industries
Navigator Business Solutions, an SAP implementation Gold Partner, has just released a pair of turnkey ERP solutions tailored specifically for medical device and pharmaceutical manufacturers.More \232aNavigator Business Solutions, an SAP implementation Gold Partner, has just released a pair of turnkey ERP solutions tailored specifically for medical device and pharmaceutical manufacturers.More \232aXPS Market to Reach $712.4 Million With 6.2% CAGR by 2022 | Million Insights
XPS Market to Reach $712.4 Million With 6.2% CAGR by 2022 | Million Insights
The global X-Ray Photoelectron Spectroscopy (XPS) Market was valued at USD 439.64 million in 2014 and is expected to reach USD 712.4 million by 2022, with a CAGR of 6.2%. XPS is a surface-sensitive measureable...More \232aThe global X-Ray Photoelectron Spectroscopy (XPS) Market was valued at USD 439.64 million in 2014 and is expected to reach USD 712.4 million by 2022, with a CAGR of 6.2%. XPS is a surface-sensitive measureable...More \232aGlobal Integrated Devices for Reconstituting Injectables Market 2018 - Development, Industry and Markets Report
Global Integrated Devices for Reconstituting Injectables Market 2018 - Development, Industry and Markets Report
The "Integrated Devices for Reconstituting Injectables" report has been added to ResearchAndMarkets.com's offering. The inherent instability of biological drugs is a limitation that has a direct impact on the drug...More \232aThe "Integrated Devices for Reconstituting Injectables" report has been added to ResearchAndMarkets.com's offering. The inherent instability of biological drugs is a limitation that has a direct impact on the drug...More \232aSTEERLife Partners With Center for Structured Organic Particulate Systems (C-SOPS) USA, to Revolutionise Pharmaceuticals Manufacturing
STEERLife Partners With Center for Structured Organic Particulate Systems (C-SOPS) USA, to Revolutionise Pharmaceuticals Manufacturing
STEERLife, provider of technology platforms and process solutions for pharmaceutical industry, announced a partnership with the Center for Structured Organic Particulate Systems (C-SOPS), USA, to foster transformation of...More \232aSTEERLife, provider of technology platforms and process solutions for pharmaceutical industry, announced a partnership with the Center for Structured Organic Particulate Systems (C-SOPS), USA, to foster transformation of...More \232aSingle-Cell Genome Sequencing Market Worth $2.5 Billion by 2025: Grand View Research, Inc.
Single-Cell Genome Sequencing Market Worth $2.5 Billion by 2025: Grand View Research, Inc.
The global single-cell genome sequencing market size is expected to reach USD 2.49 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 14.64% during the forecast period....More \232aThe global single-cell genome sequencing market size is expected to reach USD 2.49 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 14.64% during the forecast period....More \232aAmerican Skin Association Announces Abby S. And Howard P. Milstein Innovation Award For Melanoma/Non-Melanoma Skin Cancer Research
American Skin Association Announces Abby S. And Howard P. Milstein Innovation Award For Melanoma/Non-Melanoma Skin Cancer Research
During its annual Spring Gala at The Plaza Hotel last Tuesday evening, American Skin Association (ASA) Chairman, Howard P. Milstein, announced the Abby S. and Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma...More \232aDuring its annual Spring Gala at The Plaza Hotel last Tuesday evening, American Skin Association (ASA) Chairman, Howard P. Milstein, announced the Abby S. and Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma...More \232aBERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types
BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts describing progress on translational preclinical data on display at the...More \232aBERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts describing progress on translational preclinical data on display at the...More \232aRigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients...More \232aRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients...More \232aEgalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position
Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position
Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that...More \232aEgalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that...More \232aRemarks from FDA Commissioner Scott Gottlieb, M.D., on Fiscal Year 2019 budget request for FDA
Remarks from FDA Commissioner Scott Gottlieb, M.D., on Fiscal Year 2019 budget request for FDA
Chairman Aderholt, Ranking Member Bishop, and Members of the Subcommittee. I'd like to thank the Committee for your commitment to FDA. We've been fortunate to receive strong bipartisan support in recent years. And...More \232aChairman Aderholt, Ranking Member Bishop, and Members of the Subcommittee. I'd like to thank the Committee for your commitment to FDA. We've been fortunate to receive strong bipartisan support in recent years. And...More \232aElios Therapeutics Presents Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Elios Therapeutics Presents Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Elios Therapeutics, a biopharmaceutical company developing innovative particle-delivered, dendritic cell vaccines in oncology, today presented initial open-label results from the ongoing Phase 2b clinical trial of the...More \232aElios Therapeutics, a biopharmaceutical company developing innovative particle-delivered, dendritic cell vaccines in oncology, today presented initial open-label results from the ongoing Phase 2b clinical trial of the...More \232aDelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company presented a...More \232aDelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company presented a...More \232aUS Generic Drug Market Report 2018: Industry Trends, Share, Size, Growth, Opportunity and Forecasts to 2023
US Generic Drug Market Report 2018: Industry Trends, Share, Size, Growth, Opportunity and Forecasts to 2023
The "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive insight into the...More \232aThe "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive insight into the...More \232aMedical Display Market - Global Forecast to 2023
Medical Display Market - Global Forecast to 2023
The "Medical Display Market by Technology (LED, OLED) Panel Size (=22.9, 27.0-41.9, =42) Resolution (=2MP, 4.1-8MP, =8MP), Application (Radiology, Mammography, Digital Pathology, Multi-modality, Surgical), & Display...More \232aThe "Medical Display Market by Technology (LED, OLED) Panel Size (=22.9, 27.0-41.9, =42) Resolution (=2MP, 4.1-8MP, =8MP), Application (Radiology, Mammography, Digital Pathology, Multi-modality, Surgical), & Display...More \232aGlobal Scintillators Market Analysis 2016-2018 Forecast to 2025 - Rising Adoption in Developed Economies / Countries
Global Scintillators Market Analysis 2016-2018 Forecast to 2025 - Rising Adoption in Developed Economies / Countries
The "Scintillators Market to 2025 - Global Analysis and Forecasts by Material Composition, Industries and End Products" report has been added to ResearchAndMarkets.com's offering. The scintillators market is estimated...More \232aThe "Scintillators Market to 2025 - Global Analysis and Forecasts by Material Composition, Industries and End Products" report has been added to ResearchAndMarkets.com's offering. The scintillators market is estimated...More \232aGlobal Micro-Pump Market Research Report - Forecast to 2027
Global Micro-Pump Market Research Report - Forecast to 2027
Introduction Globally the market for micro-pump is increasing rapidly. Micro-pumps have been playing a crucial role in the pharmaceutical industry for last few years. Especially in the processes such as drug discovery,...More \232aIntroduction Globally the market for micro-pump is increasing rapidly. Micro-pumps have been playing a crucial role in the pharmaceutical industry for last few years. Especially in the processes such as drug discovery,...More \232aEiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver...More \232aEiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver...More \232aGlobal 3D Medical Imaging Services Market Expected to Reach $236,809 Million by 2023 - Allied Market Research
Global 3D Medical Imaging Services Market Expected to Reach $236,809 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "3D medical imaging services Market by Technique, Application and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global...More \232aAccording to a new report published by Allied Market Research, titled, "3D medical imaging services Market by Technique, Application and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global...More \232aGlobal Arthroscopy Instruments Market Report 2018-2022 - Projected to Reach $5.61 Billion
Global Arthroscopy Instruments Market Report 2018-2022 - Projected to Reach $5.61 Billion
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 17, 2018 /PRNewswire/ -- The "Arthroscopy Instruments Market by Type (Implants, Arthroscope, Visualization System, Surgical Shaver, RF Ablation, Fluid Man...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, April 17, 2018 /PRNewswire/ -- The "Arthroscopy Instruments Market by Type (Implants, Arthroscope, Visualization System, Surgical Shaver, RF Ablation, Fluid Man...More \232aTorque Presents Preclinical Data at AACR Demonstrating that Deep-Primed IL-15 and Deep-Primed IL-12 Anchored to T Cells are Superior to Systemically Administered IL-15 and IL-12 for Increasing T Cell Infiltration and Tumor Killing Without Systemic Toxicit
Torque Presents Preclinical Data at AACR Demonstrating that Deep-Primed IL-15 and Deep-Primed IL-12 Anchored to T Cells are Superior to Systemically Administered IL-15 and IL-12 for Increasing T Cell Infiltration and Tumor Killing Without Systemic Toxicit
Torque, an immuno-oncology company developing Deep Primed™ cellular therapies with pharmacologic control to direct immune power deep within the tumor microenvironment, announced today preclinical data for the company's...More \232aTorque, an immuno-oncology company developing Deep Primed™ cellular therapies with pharmacologic control to direct immune power deep within the tumor microenvironment, announced today preclinical data for the company's...More \232aTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that new data from studies of VIBATIV® (telavancin) will be presented at the 28th European Congress of Clinical...More \232aTheravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that new data from studies of VIBATIV® (telavancin) will be presented at the 28th European Congress of Clinical...More \232aOrthoTrophix Will Present Data on Long-Term Clinical Benefit of TPX-100 in Mild to Severe Knee Osteoarthritis Patients at OARSI Annual Meeting 2018
OrthoTrophix Will Present Data on Long-Term Clinical Benefit of TPX-100 in Mild to Severe Knee Osteoarthritis Patients at OARSI Annual Meeting 2018
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100...More \232aOrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100...More \232aAnitoa Ultra-low Light Bio-optical Sensor in Volume Production
Anitoa Ultra-low Light Bio-optical Sensor in Volume Production
Anitoa Systems, ("Anitoa"), a Menlo Park CA startup since 2012, today announced the volume production release of its single chip Ultra-low-light CMOS bio-optical sensor, ULS24. Capable of 3x10-6 lux low-light detection,...More \232aAnitoa Systems, ("Anitoa"), a Menlo Park CA startup since 2012, today announced the volume production release of its single chip Ultra-low-light CMOS bio-optical sensor, ULS24. Capable of 3x10-6 lux low-light detection,...More \232aGlobal Pharmaceutical Excipients Markets Report 2018: Data for 2016-2017 & CAGR Projections for 2018-2022 - Overview, Classification & Significance in the Pharma Industry
Global Pharmaceutical Excipients Markets Report 2018: Data for 2016-2017 & CAGR Projections for 2018-2022 - Overview, Classification & Significance in the Pharma Industry
The "Excipients in Pharmaceuticals: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering. This report on the pharmaceutical excipient market covers an overview of excipients,...More \232aThe "Excipients in Pharmaceuticals: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering. This report on the pharmaceutical excipient market covers an overview of excipients,...More \232aAntimicrobial Innovator Amicrobe, Inc. Positions Management Team In Anticipation Of Product Trials
Antimicrobial Innovator Amicrobe, Inc. Positions Management Team In Anticipation Of Product Trials
Amicrobe, Inc., a company that uses advanced bioengineering principles to develop novel antimicrobial products for the era of antibiotic resistance, today announced the recent hiring of Doug Looker, Ph.D., who will join...More \232aAmicrobe, Inc., a company that uses advanced bioengineering principles to develop novel antimicrobial products for the era of antibiotic resistance, today announced the recent hiring of Doug Looker, Ph.D., who will join...More \232a
PR Newswire IndexMore>>
Entertainment News Releases via PRNewswire
Entertainment
Entertainment News Releases via PRNewswire
Travel
Travel News Releases via PRNewswire
Political Campaigns
Political Campaigns News Releases via PRNewswire
Medicine & Pharmaceuticals
Medicine & Pharmaceuticals News Releases via PRNewswire
Film & Motion Picture News Releases via PRNewswire
Film & Motion Picture
Film & Motion Picture News Releases via PRNewswire
Economic News and Analysis
Economic News Releases via PRNewswire
Computer Software
Computer Software News Releases via PRNewswire
Computer Networks
Computer Networks News Releases via PRNewswire
Computer Hardware
Computer Hardware News Releases via PRNewswire
Biotech News Releases via PRNewswire
Biotechnology
Biotechnology News Releases via PRNewswire
